Myriad Genetics completes business negotiations with Melanoma Diagnostics
Myriad Genetics has struck a deal that sees it acquire technology used in the diagnosis of malignant melanoma.
Myriad Genetics has concluded its business negotiations with Melanoma Diagnostics in a deal that sees the firm acquire propriety technology to assist with the prognosis and diagnosis of malignant melanoma.
As part of the agreement, the company, which states its strategy is to understand the part genes play in human disease, has all rights to commercialise any tests derived from the acquisition.
Commenting on the deal, president of Myriad Genetic Technologies Mark Capone said: "This will expand our presence in the solid tumour market as we develop a dermatology commercialisation team."
Dr Kevin Scanlon, chief executive of Melanoma Diagnostics noted the sale of its technology to Myriad will help towards the future development of novel molecular diagnostic tests.
These latest business negotiations come after Aggreko, the temporary power and control company, acquired Northland Power Services - a supplier of energy solutions - for a maximum consideration of $26 million (£16.6 million).